InSitu Biologics
Oakdale, MN · Healthcare, Manufacturing · 9 employees
InSitu Biologics is an emerging biotech company focused on development of a multi-phase prolonged release drug delivery platform for localized treatment of pain, cancer, and infection. We use disruptive technology to address unmet needs in the pain management and drug delivery markets.
Funding history
- Series seed — $4.0M — Dec 2025
- Series seed — $3.0M — Dec 2023
- Funding Round — Undisclosed — Dec 2017
- Funding Round — Undisclosed — Nov 2017
Recent signals
- Dec 18, 2025: Raised $4.0M in Series seed
- Dec 29, 2023: Raised $3.0M in Series seed
- Dec 07, 2017: Raised Undisclosed
- Nov 22, 2017: Raised Undisclosed
See plans & pricing → Track InSitu Biologics’s funding, hiring, and signals — with verified contacts — on Fundz.